NCT00165698View on ClinicalTrials.gov

Efficacy and Safety Study on Menatetrenone in the Treatment of Postmenopausal Osteoporosis Women

PHASE3CompletedINTERVENTIONAL
Enrollment

240

Participants

Timeline

Start Date

May 31, 2005

Primary Completion Date

January 31, 2007

Study Completion Date

July 31, 2007

Conditions
Postmenopausal Osteoporosis
Interventions
DRUG

menatetranone

15 mg three times a day orally for 12 months

DRUG

alfacalcidol

0.25 μg twice a day orally for 12 months

Trial Locations (5)

Unknown

Beijing Hospital, Beijing

Chinese PLA General Hospital, Beijing

Peking Union Medical College Hospital, Beijing

Hua Dong Hospital, Shanghai

The Sixth People's Hospital affiliated to Shanghai Jiaopong University, Shanghai

All Listed Sponsors
lead

Eisai Co., Ltd.

INDUSTRY

NCT00165698 - Efficacy and Safety Study on Menatetrenone in the Treatment of Postmenopausal Osteoporosis Women | Biotech Hunter | Biotech Hunter